Journal of Clinical Oncology, Vol 14, 792-795, Copyright © 1996 by American Society of Clinical Oncology

ARTICLES

Paclitaxel has moderate activity in squamous cervix cancer. A Gynecologic Oncology Group study

WP McGuire, JA Blessing, D Moore, SS Lentz and G Photopulos
Department of Medicine, Emory University, Atlanta, GA, USA.

PURPOSE: Taxol (paclitaxel; Bristol-Myers Squibb, Princeton, NJ) is a new antineoplastic drug with broad-spectrum activity in solid tumors, including epithelial ovarian cancer, head and neck cancer, esophageal cancer, breast cancer, bladder cancer, and lung cancer. Its unique mechanism of action, polymerization of tubulin monomers, has stimulated both clinical and preclinical research on this agent. As limited drug supplies became more plentiful, a phase II trial of Taxol was initiated in patients with advanced squamous cervix cancer who had received no prior chemotherapy. PATIENTS AND METHODS: In this trial, 30 assessable patients were initially entered onto the study and four partial responses were seen. Further accrual of 22 assessable patients was then accomplished to define better the response rate with smaller confidence intervals. The starting dose of Taxol was 170 mg/m2 (135 mg/m2 for patients with prior pelvic radiation) given as a 24-hour continuous intravenous infusion with courses repeated every 3 weeks. Dose escalations to 200 mg/m2 and deescalations to 110 mg/m2 were allowed based on adverse effects. RESULTS: The final response rate was 17% (two complete responses and seven partial responses). The primary and dose- limiting toxicity was neutropenia. CONCLUSION: The response rate makes Taxol a drug with sufficient activity to explore it in combination with other agents with similar activity.
CiteULike    Complore    Connotea    Del.icio.us    Digg    Facebook    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				P. O. Witteveen, J. van der Velden, I. Vergote, C. Guerra, C. Scarabeli, C. Coens, G. Demonty, and N. Reed Phase II study on paclitaxel in patients with recurrent, metastatic or locally advanced vulvar cancer not amenable to surgery or radiotherapy: a study of the EORTC-GCG (European Organisation for Research and Treatment of Cancer--Gynaecological Cancer Group) Ann. Onc., June 1, 2009; (2009) mdp043v1. [Abstract] [Full Text] [PDF]

				G. Mountzios, M. A. Dimopoulos, A. Bamias, G. Vourli, H. Kalofonos, G. Aravantinos, G. Fountzilas, and C. A. Papadimitriou Randomized multicenter phase II trial of cisplatin and ifosfamide with or without paclitaxel in recurrent or metastatic carcinoma of the uterine cervix: a Hellenic Cooperative Oncology Group (HeCOG) study Ann. Onc., May 20, 2009; (2009) mdn797v1. [Abstract] [Full Text] [PDF]

				H. J. Long III Management of Metastatic Cervical Cancer: Review of the Literature J. Clin. Oncol., July 10, 2007; 25(20): 2966 - 2974. [Abstract] [Full Text] [PDF]

				H. J. Long III, B. N. Bundy, E. C. Grendys Jr, J. A. Benda, D. S. McMeekin, J. Sorosky, D. S. Miller, L. A. Eaton, and J. V. Fiorica Randomized Phase III Trial of Cisplatin With or Without Topotecan in Carcinoma of the Uterine Cervix: A Gynecologic Oncology Group Study J. Clin. Oncol., July 20, 2005; 23(21): 4626 - 4633. [Abstract] [Full Text] [PDF]

				A. Buda, R. Fossati, N. Colombo, F. Fei, I. Floriani, D. Gueli Alletti, D. Katsaros, F. Landoni, A. Lissoni, C. Malzoni, et al. Randomized Trial of Neoadjuvant Chemotherapy Comparing Paclitaxel, Ifosfamide, and Cisplatin With Ifosfamide and Cisplatin Followed by Radical Surgery in Patients With Locally Advanced Squamous Cell Cervical Carcinoma: The SNAP01 (Studio Neo-Adjuvante Portio) Italian Collaborative Study J. Clin. Oncol., June 20, 2005; 23(18): 4137 - 4145. [Abstract] [Full Text] [PDF]

				D. H. Moore, J. A. Blessing, R. P. McQuellon, H. T. Thaler, D. Cella, J. Benda, D. S. Miller, G. Olt, S. King, J. F. Boggess, et al. Phase III Study of Cisplatin With or Without Paclitaxel in Stage IVB, Recurrent, or Persistent Squamous Cell Carcinoma of the Cervix: A Gynecologic Oncology Group Study J. Clin. Oncol., August 1, 2004; 22(15): 3113 - 3119. [Abstract] [Full Text] [PDF]

				P. G. Rose Combined-Modality Therapy of Locally Advanced Cervical Cancer J. Clin. Oncol., May 15, 2003; 21(90100): 211s - 217. [Abstract] [Full Text] [PDF]

				J. V. Fiorica Update on the Treatment of Cervical and Uterine Carcinoma: Focus on Topotecan Oncologist, October 1, 2002; 7(90005): 36 - 45. [Abstract] [Full Text] [PDF]

				J. D. Bloss, J. A. Blessing, B. C. Behrens, R. S. Mannel, J. S. Rader, A. K. Sood, M. Markman, and J. Benda Randomized Trial of Cisplatin and Ifosfamide With or Without Bleomycin in Squamous Carcinoma of the Cervix: A Gynecologic Oncology Group Study J. Clin. Oncol., April 1, 2002; 20(7): 1832 - 1837. [Abstract] [Full Text] [PDF]

				S. Ota, T. Sugiyama, K. Komai, N. Hirai, S. Kumagai, K. Ushijima, T. Nishida, and T. Kamura Weekly 1 Hour Paclitaxel Infusion in Patients with Recurrent Gynecological Tumors: a Pilot Study Jpn. J. Clin. Oncol., August 1, 2001; 31(8): 395 - 398. [Abstract] [Full Text] [PDF]

				J. P. Curtin, J. A. Blessing, K. D. Webster, P. G. Rose, A. R. Mayer, W. C. Fowler Jr, J. H. Malfetano, and R. D. Alvarez Paclitaxel, an Active Agent in Nonsquamous Carcinomas of the Uterine Cervix: A Gynecologic Oncology Group Study J. Clin. Oncol., March 1, 2001; 19(5): 1275 - 1278. [Abstract] [Full Text] [PDF]

				Z. Duan, A. J. Feller, R. T. Penson, Bruce. A. Chabner, and M. V. Seiden Discovery of Differentially Expressed Genes Associated with Paclitaxel Resistance Using cDNA Array Technology: Analysis of Interleukin (IL) 6, IL-8, and Monocyte Chemotactic Protein 1 in the Paclitaxel-resistant Phenotype Clin. Cancer Res., November 1, 1999; 5(11): 3445 - 3453. [Abstract] [Full Text] [PDF]

				C. Lhomme, P. Fumoleau, P. Fargeot, Y. Krakowski, V. Dieras, J. Chauvergne, P. Vennin, P. Rebattu, H. Roche, J.-L. Misset, et al. Results of a European Organization for Research and Treatment of Cancer/Early Clinical Studies Group Phase II Trial of First-Line Irinotecan in Patients With Advanced or Recurrent Squamous Cell Carcinoma of the Cervix J. Clin. Oncol., October 1, 1999; 17(10): 3136 - 3142. [Abstract] [Full Text] [PDF]

				P. G. Rose, J. A. Blessing, D. M. Gershenson, and R. McGehee Paclitaxel and Cisplatin as First-Line Therapy in Recurrent or Advanced Squamous Cell Carcinoma of the Cervix: A Gynecologic Oncology Group Study J. Clin. Oncol., September 1, 1999; 17(9): 2676 - 2676. [Abstract] [Full Text] [PDF]

				C. A. Papadimitriou, K. Sarris, L. A. Moulopoulos, G. Fountzilas, A. Anagnostopoulos, Z. Voulgaris, D. Gika, N. Giannakoulis, E. Diakomanolis, and M. A. Dimopoulos Phase II Trial of Paclitaxel and Cisplatin in Metastatic and Recurrent Carcinoma of the Uterine Cervix J. Clin. Oncol., March 1, 1999; 17(3): 761 - 761. [Abstract] [Full Text] [PDF]